Biotech Startup Mekonos raises oversubscribed $25 million round to overcome pharma industry's cell & gene therapy delivery hurdles

Mekonos, Inc. | November 10, 2021

Mekonos, a biotech company building the future of cell therapies on a chip, has raised $25M in an oversubscribed Series A round co-led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic Capital, a division of PEAK6 Investments. New institutional and strategic investors, including Section 32, Sands Capital, TDK Ventures, and the venture arm of Debiopharm, and previous investors, including Novartis Pharma AG (dRx Capital) and Elementum Ventures, also joined in the funding round that will support Mekonos' next stages in product development and commercialization.

Mekonos has developed a novel chip technology platform that supports ex-vivo delivery of cell payloads at the single cell level. The platform allows for multi-payload physical delivery – multiplexing – into cells with repeatable and localized dose control for precise and scalable cell engineering. Demonstration pilot projects with top pharmaceutical and research labs have shown outstanding cell viability and uptake in delivery of CRISPR and other payloads into immune cells, stem cells, and other fragile cell types.

"Mekonos' novel technology is solving a critical pain point in an area of cell and gene therapy that hasn't seen significant innovation in 20+ years," said Neil Tiwari, who is joining Mekonos' Board of Directors to represent the lead investors. "Mekonos has an exceptional leadership team equipped to further the impact of its technology and partnerships. The company is well-positioned to play a lead role in the significant and fast-growing addressable market for cell and gene therapy solutions that deliver accessible personalized medicine."

"Mekonos is bringing truly disruptive cell engineering technology to reality. This investment aligns well with our aim to support the development of novel drug delivery systems and further explore the possibilities that digital platforms can bring to science and ultimately patients. We look forward to observing firsthand the improvements that Mekonos' plateform can bring to cell and gene therapeutics,"

 Lambert Potin, Partnering Associate, Search and Evaluation, Debiopharm

Mekonos will use the new capital to expand its MEMS, Microfluidics, Biology, and Business Development functions in order to advance its proprietary, integrated system-on-a-chip (SoC) for targeted ex vivo gene engineering. Jake Lesnik, previously an executive at System Biosciences, has also joined as VP of Business Development to expand partnerships and drive commercial strategy for Mekonos' market-leading cell engineering and therapeutics development platform.

"announcement is a clear signal that Mekonos is building critical infrastructure to unlock personalized medicine at scale and enable cell engineering across life science verticals. We are proud and humbled to work with top tier venture and strategic investors, and to exceed our initial goals for this fundraising round," said Anil Narasimha, CEO and Co-founder of Mekonos. "We are excited to partner with leading investors who share our vision for developing a new era of cell engineering that can simplify individualized treatments across disease spaces."

About Mekonos, Inc.
Mekonos is an enabling technology company transforming synthetic biology and personalized medicine. The company's SoC merges innovations in MEMS, microfluidics, and chemistry for controlled and individualized molecular delivery in cells at scale. The company is headquartered in San Francisco, is backed by leading investors in both healthcare and technology, and is an alum of Berkeley Launch, Berkeley SkyDeck, Creative Destruction Lab, and named a 2018 Fierce 15 startup.


This infographic gathers 10 of the best HIV treatments in Europe’s pipeline that will help doctors worldwide fight against AIDS better than ever before.


This infographic gathers 10 of the best HIV treatments in Europe’s pipeline that will help doctors worldwide fight against AIDS better than ever before.

Related News


Spotlight Therapeutics Closes its Series A Financing Bringing the Total Raised to $30 Million

Spotlight Therapeutics | December 01, 2020

Spotlight Therapeutics, Inc., a biotechnology organization creating non-viral quality altering therapeutics for direct in vivo altering of target genes, closed its Series A financing bringing the complete raised to $30 million. The financing was driven by GV, in the past Google Ventures, with interest from extra undisclosed investors. Realizing the full revolutionary potential of CRISPR genome editing requires the ability to edit target genes directly in the right cells of the human body. Spotlight's proprietary technology platform develops programmable CRISPR ribonucleoproteins (RNPs) optimized for in vivo cell-targeted delivery. The modular biologics approach is designed to avoid the complexity and toxicities associated with current cell, viral and nanoparticle delivery methods. Spotlight’s technology integrates the game-changing power of CRISPR with well-established biologics precepts. The company is advancing lead programs in hemoglobinopathies and immuno-oncology.

Read More


PhageNova Bio, Inc. Announces Publication Describing New Method for Safe and Effective Pulmonary Delivery of Therapeutics

PhageNova Bio, Inc. | December 14, 2020

PhageNova Bio, Inc. ("PhageNova") is pleased to declare the distribution of information created through a sponsored research agreement with Rutgers, The State University of New Jersey. The Med (a Cell Press distribution) article, entitled Targeted Phage Display-Based Pulmonary Vaccination in Mice and Non-human Primates, portrays another technique for protected and effective pulmonary delivery of therapeutics, including an aerosol vaccination strategy which is being developed to address the current SARS-CoV-2 pandemic. "Our targeted method of pulmonary delivery is the initial step towards the development of aerosol phage-based vaccines for human applications against multiple diseases," says Renata Pasqualini, PhD, co-senior study author, Founder and Chief Scientific Officer of PhageNova, and Chief of the Division of Cancer Biology, Department of Radiation Oncology at Rutgers Cancer Institute and Rutgers New Jersey Medical School. "Other advantages of phage particles are that they are highly stable under harsh environmental conditions, and their large-scale production is extremely cost-effective compared with other vaccine strategies because they don't need to be refrigerated, which is a particularly important requirement for the developing world."

Read More

Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company

Vedere Bio | October 29, 2020

Vedere Bio, Inc. (Vedere Bio), a stealth-stage company focused on advancing photoreceptor-protein-based optogenetic therapies that are delivered to the retina intravitreally to restore functional vision, announced today that it has been acquired by Novartis. Shareholders in Vedere Bio received $150 million upfront and will be eligible for up to $130 million in milestone payments, for a total of $280 million. Based on technology from the laboratories of Drs. Ehud Isacoff and John G. Flannery of UC Berkeley, and technology directed at enhanced ocular gene therapy delivery arising jointly between UC Berkeley and the School of Veterinary Medicine at the University of Pennsylvania, Vedere Bio was formed in the Atlas Venture incubator in June 2019. The company was launched with a $21 million Series A financing and began lab operations at LabCentral in Cambridge, MA where it advanced its lead programs from concept to development candidate within one year. Immediately prior to the acquisition, certain earlier-stage vision restoration and vision preservation assets leveraging the company's ocular gene therapy toolbox were spun out into a newly formed entity – Vedere Bio II, Inc.

Read More